TNF and inflammatory bowel disease: However, in the UC management algorithm there was disagreement with the recommendation to escalate directly from 5-ASA to anti-TNF or vedolizumab due to prescribing restrictions in Australia, which have previously been reported to be a barrier for adherence to IBD guidelines [10].